
Plus Therapeutics PSTV
$ 5.8
2.7%
Annual report 2025
added 03-12-2026
Plus Therapeutics Total Current Liabilities 2011-2026 | PSTV
Annual Total Current Liabilities Plus Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.3 M | 15.6 M | 10.7 M | 11.9 M | 5.87 M | 8.54 M | 14.5 M | 17.6 M | 18.4 M | 12.5 M | 8.44 M | 15.9 M | 14.9 M | 17.6 M | 7.82 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18.4 M | 5.87 M | 12.8 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
228 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
22.9 M | - | - | $ 86.2 M | ||
|
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
1.47 B | $ 325.52 | -2.36 % | $ 42.6 B | ||
|
Applied Molecular Transport
AMTI
|
15.1 M | - | - | $ 10.1 M | ||
|
I-Mab
IMAB
|
576 M | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
9.71 M | - | 4.14 % | $ 49.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
Aligos Therapeutics
ALGS
|
21.2 M | $ 8.05 | 8.49 % | $ 79.6 M | ||
|
Allakos
ALLK
|
36.6 M | - | - | $ 28.6 M | ||
|
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
Applied Therapeutics
APLT
|
71.2 M | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
6.29 M | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
22.1 M | - | -13.39 % | $ 1.45 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
158 M | $ 21.88 | 0.92 % | $ 1.02 B | ||
|
Cabaletta Bio
CABA
|
50.2 M | $ 3.49 | 2.65 % | $ 351 M | ||
|
CymaBay Therapeutics
CBAY
|
36.8 M | - | - | $ 3.45 B | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.73 M | $ 3.15 | -0.63 % | $ 5.19 M | ||
|
AgeX Therapeutics
AGE
|
3.56 M | - | -10.17 % | $ 12.2 K | ||
|
ContraFect Corporation
CFRX
|
20.8 M | - | -5.16 % | $ 5.39 M | ||
|
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
163 M | $ 1.38 | -10.97 % | $ 355 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
47.6 M | $ 4.22 | -0.59 % | $ 451 M | ||
|
Arcutis Biotherapeutics
ARQT
|
130 M | $ 23.88 | -2.85 % | $ 3.04 B | ||
|
AIkido Pharma
AIKI
|
1.61 M | - | 1.93 % | $ 17.4 M | ||
|
BioDelivery Sciences International
BDSI
|
82.4 M | - | -4.8 % | $ 255 M | ||
|
Autolus Therapeutics plc
AUTL
|
73.4 M | $ 1.53 | 2.35 % | $ 407 M | ||
|
Aptose Biosciences
APTO
|
9.31 M | - | -45.71 % | $ 1.2 M | ||
|
BeiGene, Ltd.
BGNE
|
1.83 B | - | 0.49 % | $ 251 B | ||
|
Checkpoint Therapeutics
CKPT
|
20.1 M | - | - | $ 169 M | ||
|
Caladrius Biosciences
CLBS
|
5.61 M | - | -16.75 % | $ 25.8 M | ||
|
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | ||
|
Clearside Biomedical
CLSD
|
6.81 M | - | - | $ 25.3 M | ||
|
Celldex Therapeutics
CLDX
|
51 M | $ 33.66 | -0.63 % | $ 2.24 B | ||
|
bluebird bio
BLUE
|
200 M | - | - | $ 546 M | ||
|
CNS Pharmaceuticals
CNSP
|
4.1 M | $ 2.7 | -1.81 % | $ 1.2 M |